Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Regulation of androgen receptor signaling by ubiquitination during folliculogenesis and its possible dysregulation in polycystic ovarian syndrome.

Lim JJ, Lima PDA, Salehi R, Lee DR, Tsang BK.

Sci Rep. 2017 Aug 31;7(1):10272. doi: 10.1038/s41598-017-09880-0.

2.

Chemoresistance and targeted therapies in ovarian and endometrial cancers.

Brasseur K, GĂ©vry N, Asselin E.

Oncotarget. 2017 Jan 17;8(3):4008-4042. doi: 10.18632/oncotarget.14021.

3.
4.

FLIP the Switch: Regulation of Apoptosis and Necroptosis by cFLIP.

Tsuchiya Y, Nakabayashi O, Nakano H.

Int J Mol Sci. 2015 Dec 18;16(12):30321-41. doi: 10.3390/ijms161226232. Review.

5.

"Ziziphus jujuba": A red fruit with promising anticancer activities.

Tahergorabi Z, Abedini MR, Mitra M, Fard MH, Beydokhti H.

Pharmacogn Rev. 2015 Jul-Dec;9(18):99-106. doi: 10.4103/0973-7847.162108. Review.

6.

Synergistic anticancer effect of cisplatin and Chal-24 combination through IAP and c-FLIPL degradation, Ripoptosome formation and autophagy-mediated apoptosis.

Shi S, Wang Q, Xu J, Jang JH, Padilla MT, Nyunoya T, Xing C, Zhang L, Lin Y.

Oncotarget. 2015 Jan 30;6(3):1640-51.

7.

A delay prior to mitotic entry triggers caspase 8-dependent cell death in p53-deficient Hela and HCT-116 cells.

Silva VC, Plooster M, Leung JC, Cassimeris L.

Cell Cycle. 2015;14(7):1070-81. doi: 10.1080/15384101.2015.1007781.

8.

Cell fate regulation by gelsolin in human gynecologic cancers.

Abedini MR, Wang PW, Huang YF, Cao M, Chou CY, Shieh DB, Tsang BK.

Proc Natl Acad Sci U S A. 2014 Oct 7;111(40):14442-7. doi: 10.1073/pnas.1401166111. Epub 2014 Sep 22. Erratum in: Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17684.

9.

Phytochemicals: a multitargeted approach to gynecologic cancer therapy.

Farrand L, Oh SW, Song YS, Tsang BK.

Biomed Res Int. 2014;2014:890141. doi: 10.1155/2014/890141. Epub 2014 Jul 1. Review.

10.

The diarylheptanoid hirsutenone sensitizes chemoresistant ovarian cancer cells to cisplatin via modulation of apoptosis-inducing factor and X-linked inhibitor of apoptosis.

Farrand L, Kim JY, Byun S, Im-aram A, Lee J, Suh JY, Lee KW, Lee HJ, Tsang BK.

J Biol Chem. 2014 Jan 17;289(3):1723-31. doi: 10.1074/jbc.M113.513879. Epub 2013 Nov 18.

11.

The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.

Im-aram A, Farrand L, Bae SM, Song G, Song YS, Han JY, Tsang BK.

PLoS One. 2013 Sep 23;8(9):e75455. doi: 10.1371/journal.pone.0075455. eCollection 2013.

12.

Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission.

Farrand L, Byun S, Kim JY, Im-Aram A, Lee J, Lim S, Lee KW, Suh JY, Lee HJ, Tsang BK.

J Biol Chem. 2013 Aug 16;288(33):23740-50. doi: 10.1074/jbc.M113.487686. Epub 2013 Jul 5.

13.

Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.

Godwin P, Baird AM, Heavey S, Barr MP, O'Byrne KJ, Gately K.

Front Oncol. 2013 May 16;3:120. doi: 10.3389/fonc.2013.00120. eCollection 2013.

14.

Hyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cells.

Song X, Kim SY, Zhou Z, Lagasse E, Kwon YT, Lee YJ.

Cell Death Dis. 2013 Apr 4;4:e577. doi: 10.1038/cddis.2013.104.

15.

Death domain-associated protein DAXX promotes ovarian cancer development and chemoresistance.

Pan WW, Zhou JJ, Liu XM, Xu Y, Guo LJ, Yu C, Shi QH, Fan HY.

J Biol Chem. 2013 May 10;288(19):13620-30. doi: 10.1074/jbc.M112.446369. Epub 2013 Mar 28.

16.

Novel phosphorylation and ubiquitination sites regulate reactive oxygen species-dependent degradation of anti-apoptotic c-FLIP protein.

Wilkie-Grantham RP, Matsuzawa S, Reed JC.

J Biol Chem. 2013 May 3;288(18):12777-90. doi: 10.1074/jbc.M112.431320. Epub 2013 Mar 21.

17.

SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro.

Du M, Qiu Q, Gruslin A, Gordon J, He M, Chan CC, Li D, Tsang BK.

PLoS One. 2013;8(1):e54572. doi: 10.1371/journal.pone.0054572. Epub 2013 Jan 24.

18.

PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: a requirement for Akt down-regulation.

Kobayashi N, Abedini M, Sakuragi N, Tsang BK.

J Ovarian Res. 2013 Jan 26;6:7. doi: 10.1186/1757-2215-6-7. eCollection 2013.

19.

c-FLIP, a master anti-apoptotic regulator.

Safa AR.

Exp Oncol. 2012 Oct;34(3):176-84. Review.

20.

Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum.

Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, Tsang BK.

Ann N Y Acad Sci. 2012 Oct;1271:58-67. doi: 10.1111/j.1749-6632.2012.06734.x. Review. Erratum in: Ann N Y Acad Sci. 2013 Sep;1299:100.

Supplemental Content

Support Center